A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection

SARS-CoV-2, the etiological agent behind the coronavirus disease 2019 (COVID-19) pandemic, has continued to mutate and create new variants with increased resistance against the WHO-approved spike-based vaccines. With a significant portion of the worldwide population still unvaccinated and with wanin...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulton, Stephen, Poutou, Joanna, Gill, Rida, Alluqmani, Nouf, He, Xiaohong, Singaravelu, Ragunath, Crupi, Mathieu J.F., Petryk, Julia, Austin, Bradley, Angka, Leonard, Taha, Zaid, Teo, Iris, Singh, Siddarth, Jamil, Rameen, Marius, Ricardo, Martin, Nikolas, Jamieson, Taylor, Azad, Taha, Diallo, Jean-Simon, Ilkow, Carolina S., Bell, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562195/
https://www.ncbi.nlm.nih.gov/pubmed/37822719
http://dx.doi.org/10.1016/j.omtm.2023.101110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562195/
https://www.ncbi.nlm.nih.gov/pubmed/37822719
http://dx.doi.org/10.1016/j.omtm.2023.101110

Ejemplares similares